Halozyme Therapeutics: Steady Growth In A Challenged Market
Halozyme Therapeutics sees strong Q4 2024 growth, driven by ENHANZE platform royalties. Click here to find out why HALO stock ...
Genmab: GEN3014's Demise And Implications For The HexaBody Platform
Genmab wisely chose not to pursue GEN3014 further, focusing instead on its existing pipeline projects. Click here to read an ...
Genmab A/S (OTCMKTS:GNMSF) Stock Crosses Below Two Hundred Day Moving Average – Time to Sell?
Genmab A/S (OTCMKTS:GNMSF – Get Free Report) shares crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $224.14 and traded as low as ...
BioPharma Dive3d
A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV
Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...
Targeted Oncology3d
Orlowski Discusses Treatment Path Through Successive Relapses of Multiple Myeloma
During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of ...
pharmaphorum5d
J&J abandons work with Genmab on Darzalex successor
A head-to-head trial of HexaBody-CD38 versus Darzalex Faspro revealed an overall response rate (ORR) of 55% and 52%, respectively, with Genmab pointing to "deeper responses" with the new drug and a ...
Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded
Genmab (CSE:GMAB) (NASDAQ:GMAB) announced on Monday, March 10, that Johnson&Johnson (NYSE:JNJ) has chosen not to proceed with the development of GEN3014 (HexaBody-CD38), a next-gen version of their ...
William Blair upgrades Genmab with focus now on pipeline
William Blair analyst Matthew Phipps last night upgraded Genmab (GMAB) to Outperform from Market Perform without a price target. after the ...
Fierce Biotech5d
J&J opts out of licensing Genmab's Darzalex challenger after look at phase 1/2 data
Johnson & Johnson is dropping a partnership with Genmab centered around a CD38 monoclonal antibody, prompting the latter ...
The American Journal of Managed Care5d
With Sub-Q Immunotherapy Coming, “Patient Preference Has to Be the Key”
An oncologist from Atrium Health outlines how saving time administering immunotherapy could have far-reaching benefits.
JPMorgan expects ‘significant’ underperformance of Genmab shares
JPMorgan keeps a Neutral rating on Genmab (GMAB) with a DKK 1,700 price target after the company announced that Johnson & Johnson (JNJ) has ...
Investing.com Australia6d
Genmab stock tumbles after J&J opts out of licensing deal
The decision comes after Genmab provided J&J with data from a clinical proof-of-concept study, which included a head-to-head comparison with DARZALEX FASPRO® (daratumumab and hyaluronidase fihj) in ...